

RECEIVED
CENTRAL FAX CENTER

COMPLETED

DEC 07 2006

PTO/SB/96 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No./Patent No.: 6,462,058 Filed/Issue Date: OCTOBER 08, 2002

Entitled: BENZIMIDAZOLE COMPOUND CRYSTAL

TAKEDA PHARMACEUTICAL COMPANY LIMITED, a CORPORATION

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: INVENTORS To: TAKEDA CHEMICAL INDUSTRIES LTD.

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: TAKEDA CHEMICAL INDUSTRIES LTD. To: TAKEDA PHARMACEUTICAL COMPANY LIMITED

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose file is supplied below) is authorized to act on behalf of the assignee.



Signature

DOUGLAS P. MUELLER

Printed or Typed Name

DECEMBER 7, 2006

Date

612.455.3804

Telephone Number

ATTORNEY FOR APPLICANT

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

04164.74900

RECEIVED
CENTRAL FAX CENTER

DEC 07 2006

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor hereby sells and assigns, to TAKEDA CHEMICAL INDUSTRIES LTD., a corporation of Japan, 1-1, Doshomachi 4-chome, Chuo-ku, Osaka, Japan (hereinafter ASSIGNEE) all right, title and interest for the United States, its territories and possessions in and to the following invention and U.S. application filed thereon, and the entire right, title and interest in and to any and all Letters Patents which may be granted therefor in the United States, to be held and enjoyed by said ASSIGNEE, its successors, legal representatives and assigns to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by the undersigned had this Assignment not been made.

Title of Invention : Benzimidazole Compound Crystal

United States Patent Application :

☒ [XX] executed concurrently herewith☐ [] executed on _____☐ [] Serial No. _____ Filed _____

Each of the undersigned acknowledges that this sale and assignment includes any and all divisions or continuations of said United States Patent application, and any and all Letters Patent of the United States which may issue on any such applications, including any and all reissues or extensions thereof.

Each of the undersigned hereby authorizes and requests the Commissioner of Patents and Trademarks to issue any and all such Letters Patent to said ASSIGNEE, its successors or assigns in accordance herewith;

Each of the undersigned warrants and covenants that he has the full and unencumbered right to sell and assign the interests herein sold and assigned and that he has not executed and will not execute any document or instrument in conflict herewith;

Each of the undersigned further covenants and agrees he will communicate to said ASSIGNEE, its successors, legal representatives or assigns all information known to him relating to said invention or patent application and that he will execute and deliver any papers, make all rightful oaths, assist in and testify in any related proceedings including interferences or lawsuits concerning this application or continuation, division or reissue thereof, and perform all other lawful acts deemed necessary or desirable by said ASSIGNEE, its successors, legal representatives or assigns to obtain a grant of a valid United States Patent on said invention;

Each of the undersigned hereby grants ASSIGNEE and its legal representatives, the power to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment and specifically, the power to insert in the space provided above, the filing date and application number of the application when known.

In witness hereof, executed by the undersigned on the date(s) opposite the undersigned names.

NAMES AND SIGNATURES OF INVENTORS		
1.Name: Akira FUJISHIMA	Signature: <i>Akira Fujishima</i>	Date: November 1, 2000
2.Name: Isao AOKI	Signature: <i>Isao Aoki</i>	Date: November 1, 2000
3.Name: Keiji KAMIYAMA	Signature: <i>Keiji Kamiyama</i>	Date: November 1, 2000
4.Name:	Signature:	Date:
5.Name:	Signature:	Date:
6.Name:	Signature:	Date:
NAMES AND SIGNATURES OF WITNESSES*		
Name/ Yuji NISHIKIMI For: 1 - 3	Signature: <i>Yuji Nishikimi</i>	Date: November 1, 2000
Name/ Yasunori GOTO For: 1 - 3	Signature: <i>Yasunori Goto</i>	Date: November 1, 2000
Name/ For:	Signature:	Date:
Name/ For:	Signature:	Date:
Name/ For:	Signature:	Date:
Name/ For:	Signature:	Date:

*Notice for Witnesses! Please indicate which inventor(s) you are signing for by writing the corresponding numbers after "For:"



THE OSAKA CHAMBER OF COMMERCE & INDUSTRY

2-8 HONMACHIBASHI, CHUO-KU, OSAKA 540-0029, JAPAN.
FAX: (06) 6944-6248 TEL: (06) 6944-6411
URL: <http://www.osaka-cci.or.jp/>

October 13, 2004

To whom it may concern:

CERTIFICATE OF MEMBERSHIP

This is to certify that the undermentioned company is registered as a member of this Chamber.

Company name: Takeda Pharmaceutical Company Limited

(The former company name in English was
Takeda Chemical Industries, Ltd.
until June 29, 2004.)

Address: 1-1, Doshomachi 4-chome, Chuo-ku, Osaka, Japan

Membership Number: KT-01-00080

The Osaka Chamber of Commerce & Industry



YK
Yoshinobu Kobayashi
Authorized Signatory

AEP7876

PTO/SB/80

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

☒ The practitioners associated with the Customer Number: 52835
as attorneys or agents to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with patent applications identified below:

<u>Serial Number</u>	<u>Filing Date</u>	<u>Inventor(s)</u>	<u>Docket No.</u>
10/017,755	October 30, 2001	Shimizu et al.	20039.0009USC1
09/403,429	October 20, 1999	Shimizu et al.	20039.0010USWO
11/403,799	April 13, 2006	Shimizu et al.	20039.0010USC1
11/149,903	June 10, 2005	Fujishima et al.	04164.0007USC3
10/344,805	February 14, 2003	Doen et al.	20098.0001USWO
10/477,478	November 12, 2003	Yamamoto et al.	08279.1181USWO

<u>Patent Number</u>	<u>Issued Date</u>	<u>Inventor(s)</u>	<u>Docket No.</u>
6,328,994	December 11, 2001	Shimizu et al.	20039.0009USWO
7,070,805	July 4, 2006	Shimizu et al.	20039.0010USD1
6,462,058	October 8, 2002	Fujishima et al.	04164.0007USWO
6,664,276	December 16, 2003	Fujishima et al.	04164.0007USC1
6,939,971	September 6, 2005	Fujishima et al.	04164.0007USC2

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:


☒ The address associated with Customer Number: 52835

Assignee: Takeda Pharmaceutical Company Limited is a corporation organized and existing under and by virtue of the laws of the Japan, and having an office and place of business at:

1-1, Doshomachi 4-chome, Chuo-ku,
Osaka-shi, Osaka 541-0045 Japan

Signature of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee.

Signature		Date:
Name	Hiroshi AKIMOTO, Ph.D.	
Title	Managing Director, Member of the Board	

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application to which this Power of Attorney is to be filed.